Percheron Therapeutics has opened a non-renounceable entitlement offer to raise up to $2.2 million at $0.005 per share, aimed at supporting the development of its lead oncology drug candidate HMBD-002. The offer includes free attaching options exercisable at $0.01, with funds primarily to advance a planned multi-arm international phase II clinical trial targeting several cancer types. Eligible shareholders have until April 8, 2026, to participate, with new shares expected to be allotted by April 15. This capital raise is crucial for progressing HMBD-002, which has completed a phase I trial showing safety and tolerability in advanced cancer patients.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
